Every analysis.

The pCPA's quiet two-year extension keeps Canada's generic savings flowing to 2028. It also runs straight through the window in which Washington decides whether to tariff the molecules underneath them.

The 40 Hz idea is real science, contested in the places that matter, with a pivotal trial due mid-2026. The harder question is the one no one else is asking: if it works, Canada's drug-built access pipeline has nowhere to put a device — and no way to pay for it.

Health Canada cleared two generic semaglutides inside four days. The story isn't the price drop everyone reported — it's that the country just rewired the dispensing economics of its single largest drug class, and the wiring is permanent.

A two-year extension of a generic-pricing agreement is the least glamorous item of the quarter. It also governs the economics beneath roughly four of every five prescriptions dispensed in Canada.

A US tariff aimed at reshoring pharma manufacturing would land on a Canadian distribution system that is already running 1,500 active shortages on a good day. The channel risk isn't price. It's whether the molecules show up at all.

A single line in Question Period did more to define Canada's drug-reimbursement map than the Pharmacare Act itself. The program isn't expanding. It's being quietly bounded — and the boundary is now the story.

Public switching is effectively nationwide. Private plans are still paying originator prices on the same molecules — the most actionable structural inefficiency in the Canadian channel right now.

For most of its 40 years, the federal price watchdog has been a body that rarely bites. A dry procedural consultation suggests that's about to change — and patented list prices that anchor channel economics are the target.

A procedural reform to the reimbursement-review timeline reads like inside baseball. It actually moves the starting gun on every downstream channel event — pCPA negotiation, provincial listing, launch sequencing — earlier by months.

A positive reimbursement recommendation for an infused biologic in a renal-autoimmune indication is a discrete event with an outsized channel signature — it establishes a reimbursement pathway where none existed.

A reimburse-with-conditions recommendation for a durvalumab regimen in resectable gastric cancer extends an immunotherapy franchise into the perioperative setting — and the conditions attached are where the channel economics actually get decided.

The pCPA has split its negotiation pipeline into complex and non-complex tracks, and the channel-timeline consequences are larger than the procedural framing suggests.